255 related articles for article (PubMed ID: 26084611)
1. Specific combinations of the chromatin-modifying enzyme modulators significantly attenuate glioblastoma cell proliferation and viability while exerting minimal effect on normal adult stem cells growth.
Alexanian AR; Huang YW
Tumour Biol; 2015 Nov; 36(11):9067-72. PubMed ID: 26084611
[TBL] [Abstract][Full Text] [Related]
2. Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growth.
Alexanian AR; Brannon A
Med Oncol; 2022 Apr; 39(5):86. PubMed ID: 35478054
[TBL] [Abstract][Full Text] [Related]
3. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
6. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth.
Alexanian AR; Stoellinger HM; de Araujo Farias V; Quiñones-Hinojosa A
Invest New Drugs; 2023 Jun; 41(3):371-375. PubMed ID: 37162706
[TBL] [Abstract][Full Text] [Related]
8. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
[TBL] [Abstract][Full Text] [Related]
9. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
10. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
[TBL] [Abstract][Full Text] [Related]
11. The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory.
Bronner C; Chataigneau T; Schini-Kerth VB; Landry Y
Curr Med Chem; 2007; 14(25):2629-41. PubMed ID: 17979715
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Treatment Options in Urothelial Carcinoma.
Pinkerneil M; Hoffmann MJ; Niegisch G
Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
[TBL] [Abstract][Full Text] [Related]
13. Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells.
Zhu X; Mao X; Hurren R; Schimmer AD; Ezzat S; Asa SL
J Clin Endocrinol Metab; 2008 Sep; 93(9):3610-7. PubMed ID: 18544619
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
[TBL] [Abstract][Full Text] [Related]
17. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity.
Fu Y; Zhang P; Ge J; Cheng J; Dong W; Yuan H; Du Y; Yang M; Sun R; Jiang H
Int J Biochem Cell Biol; 2014 Sep; 54():68-77. PubMed ID: 25019367
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]